Navigation Links
WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
Date:1/19/2011

erGen chairman and CEO.  "We are extremely fortunate to have attracted someone of Dr. Chinnaiyan's caliber to WaferGen."

Arul M. Chinnaiyan M.D., Ph.D., Professor of Pathology and Urology, serves as Director of the Michigan Center for Translational Pathology. He co-founded Compendia Bioscience, Inc. in February 2006.  He is an Investigator at the Howard Hughes Medical Institute and S.P. Hicks endowed professor of pathology and leads a recognized research team in the field of cancer research at the University of Michigan.

Dr. Chinnaiyan has received numerous awards, including the Paul Marks Prize in Cancer Research and the AACR Outstanding Investigator Award, authored more than 200 publications, holds several U.S. patents and is funded by the National Institutes of Health, the American Cancer Society, and the Department of Defense.  He is a member of the Institute of Medicine of the National Academies of Science and serves on the National Cancer Institute's Board of Scientific Advisors.

He received his M.D. and Ph.D. degrees from the University of Michigan and is board certified in pathology.

About WaferGen and the SmartChip Real-Time PCR SystemWaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries.  The company currently offers the breakthrough SmartChip Real-Time PCR system, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The company believes that the SmartChip system is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing.  In addition, the high throughput capabilities of the SmartChip system enable scientists to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.

Combined with next-gene
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
2. WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System
3. WaferGen Reports Second Quarter 2010 Financial Results
4. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
5. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
6. WaferGen to Present at OneMedForum San Francisco 2011
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. West Pharmaceutical Services, Inc. Appoints New Director
9. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
10. Curemark Appoints Preeminent Pediatrics Gastroenterologist
11. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... WIRE via COMTEX News Network),-- Endo Pharmaceuticals ... Holdings Inc. (NASDAQ: ENDP), has presented results,from ... evaluating Frova (frovatriptan succinate) 2.5 mg,tablets as ... menstrual migraine (MM). The data demonstrated,that FROVA ...
... SALT LAKE CITY, UT, June 11, 2007 ... Genetics, Inc. (NASDAQ: MYGN) (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ... comparison of a,"Staggered Start" and a "Randomized ... Staggered Start" clinical trial,design at the Alzheimer's ...
Cached Medicine Technology:Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... Medic, the Mecklenburg EMS,Agency, has fully ... Center, which will offer the most-advanced and,challenging ... emergency,medical services personnel. Using interactive robotic ... scene and situation, trainees face evolving,scenarios controlled ...
... that it was easy to quit smoking because he did it ... why some people find it so difficult to stop smoking even ... statistics provided by the Centers for Disease Control and Prevention (CDC), ... United States, and it is the second major cause of death ...
... features include remote printing, real-time medical necessity checking, ... for draw-station future orders., MENLO PARK, Calif., ... applications for healthcare and integration software,solutions, today announced ... Blue Iris eLaborate provides a flexible, easy-to-use, web-based ...
... Synova Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today ... in aggregate notional principal amount of its,6.5% senior convertible ... common stock purchase warrants. This sale was effected as ... and warrants in the,aggregate notional principal amount of up ...
... NEW YORK Repeated courses of a drug that ... babies also may increase the risk of cerebral palsy ... study, funded by the National Institutes of Health and ... gynecology, Columbia University Medical Center and attending obstetrician and ...
... to female sex-change surgery are happy with the results, despite ... of over 200 patients in the September issue of the ... the Departments of Urology and Psychiatry at University Hospitals of ... patients who had undergone surgery and 70 who took part ...
Cached Medicine News:Health News:Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel 2Health News:Genetic variation affects smoking cessation treatment 2Health News:MITEM Releases Blue Iris eLaborate 8.6 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Repeat steroids to premature infants linked to cerebral palsy 2Health News:Most patients who have male-to-female sex-change surgery are happy, despite complications 2
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: